TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34862289

Group type: EXPERIMENTAL
Intervention: Reinforcement learning-based text messaging programme
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (standard text messaging)
Number of subjects: 60
Study: 34862296

Group type: EXPERIMENTAL
Intervention: Prospective data collection from regular follow-up visits in a comprehensive database.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardised severity coding and grading of late effects according to the Common Terminology Criteria for Adverse Events version 4.0 modified by Hudson.
Number of subjects: 0
Study: 34862297

Group type: EXPERIMENTAL
Intervention: Video consultation (VC) via telemedicine (TM)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: VAMS device for blood ASM quantitation
Number of subjects: 2
Study: 34862302

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) performed by a CBT-trained cardiac nurse plus usual care
Number of subjects: 336

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 336
Study: 34862305

Group type: EXPERIMENTAL
Intervention: Autism spectrum disorder
Number of subjects: 240

Group type: COMPARATOR
Intervention: Typically developing controls
Number of subjects: 240
Study: 34862317

Group type: EXPERIMENTAL
Intervention: COVID-DoC patients
Number of subjects: 12
Study: 34862449

Group type: EXPERIMENTAL
Intervention: HEART4U smartphone application
Number of subjects: 666

Group type: COMPARATOR
Intervention: Control group (no mHealth tool)
Number of subjects: 666
Study: 34862470

Group type: EXPERIMENTAL
Intervention: Pediatric weight management interventions
Number of subjects: 407
Study: 34862565

Group type: EXPERIMENTAL
Intervention: Group SB-1 (sleep bruxers)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Group SB-2 (bruxers identified by Bruxoff device)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Group non-SB (non-sleep bruxers)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 31
Study: 34862586

Group type: EXPERIMENTAL
Intervention: Processed burst suppression (total burst suppression)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Suppression ratio > 5 (SR > 5)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Suppression ratio > 10 (SR > 10)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Cognitive decline in composite z-score on the Alzheimer's Disease Research Center UDS Battery
Number of subjects: 167
Study: 34862610

Group type: EXPERIMENTAL
Intervention: Alcoholic hepatitis (AH)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: MELD score <15 by day 180
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Abstinence by day 180
Number of subjects: 439
Study: 34862940

Group type: EXPERIMENTAL
Intervention: Clarithromycin-based therapies (CBT) prescribed after ERADICATE Hp trial
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Clarithromycin-based therapies (CBT) prescribed after ERADICATE Hp2 trial
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Clarithromycin-based therapies (CBT) prescribed for rapid CYP2C19 metabolizers
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Real-world prescription data for H. pylori infection
Number of subjects: 125
Study: 34863019

Group type: EXPERIMENTAL
Intervention: Active treatment (Folinic Acid and Thyroid Hormone)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: All treatment groups pooled for post-hoc analysis
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Baseline GDQ
Number of subjects: 141
Study: 34863025

Group type: EXPERIMENTAL
Intervention: IgG3 donor-specific antibodies (dnDSA) from ABMR+ patients
Number of subjects: 54

Group type: COMPARATOR
Intervention: IgG3 donor-specific antibodies (dnDSA) from ABMR- patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Independent predictive factors of ABMR
Number of subjects: 54
Study: 34863120

Group type: EXPERIMENTAL
Intervention: Passive manual therapy mobilizations
Number of subjects: 38
Study: 34863122

Group type: EXPERIMENTAL
Intervention: Healthcare package including HIV, hepatitis B, and sexually transmitted infection management, pregnancy screening, and contraception
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Mobile clinics for chronic/quarterly care
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Data collection waves including clinical, socio-behavioral, biological data, and in-depth interviews
Number of subjects: 500
Study: 34863146

Group type: EXPERIMENTAL
Intervention: RISE (Risk Stratification score)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRC dyspnea score, pulmonary function tests (FEV)
Number of subjects: 0
Study: 34863198

Group type: EXPERIMENTAL
Intervention: High autonomous profile (n=52)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: High combined profile (n=25)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Moderate combined profile (n=92)
Number of subjects: 169
Study: 34863216

Group type: EXPERIMENTAL
Intervention: velaglucerase alfa 60 U/kg every 2 weeks via intravenous infusion
Number of subjects: 53
Study: 34863240

Group type: EXPERIMENTAL
Intervention: DAS-II early years GCA score
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: DAS-II early years GCA scores for 6 patients
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: DAS-II school age GCA scores
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: VABS-II Adaptive Behavior Composite (ABC) scores
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: HS-FOCUS
Number of subjects: 55
Study: 34863245

Group type: EXPERIMENTAL
Intervention: SuperFIT intervention activities implemented in the preschool setting
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SuperFIT intervention
Number of subjects: 12
Study: 34863252

Group type: EXPERIMENTAL
Intervention: Environmental health education intervention (information leaflet and workshops in a meeting room)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Environmental health education intervention (information leaflet and workshops in a real apartment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (information leaflet on EDCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Environmental health education intervention (workshops)
Number of subjects: 0
Study: 34863255

Group type: EXPERIMENTAL
Intervention: Gout-storytelling intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Stress reduction video
Number of subjects: 300
Study: 34863258

Group type: EXPERIMENTAL
Intervention: C1-inhibitor (C1-INH) 6000 IU
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 34863260

Group type: EXPERIMENTAL
Intervention: Chewing gum with Xylitol (70% w/v) as the only sweetener
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sugared chewing gum containing Maltitol (23% w/v)
Number of subjects: 0
Study: 34863270

Group type: EXPERIMENTAL
Intervention: Sound therapy
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Structured counseling
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Hearing aids
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Combination of therapies
Number of subjects: 500
Study: 34863273

Group type: EXPERIMENTAL
Intervention: Virtual pilot PCOR training program
Number of subjects: 59
Study: 34863908

Group type: EXPERIMENTAL
Intervention: GFAp at 48 hours
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Tau at 48 hours
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: GFAp AUROC at 48 hours
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Tau AUROC at 48 hours
Number of subjects: 112

Group type: COMPARATOR
Intervention: NSE AUROC at 48 hours
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: GFAp AUROC at 72 hours
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Tau AUROC at 72 hours
Number of subjects: 112

Group type: COMPARATOR
Intervention: NSE AUROC at 72 hours
Number of subjects: 112
Study: 34864079

Group type: EXPERIMENTAL
Intervention: Severe obesity (BMI ≥35 kg/m²)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Grade-I obesity
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Normal-weight
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Severe obesity without CV risk factors
Number of subjects: 1005
Study: 34864316

Group type: EXPERIMENTAL
Intervention: Feelings of control over pregnancy (survey statement: 'I feel that I have control over whether or not I get pregnant')
Number of subjects: 2594

Group type: EXPERIMENTAL
Intervention: Participants reporting poverty-level incomes
Number of subjects: 2594

Group type: EXPERIMENTAL
Intervention: Participants with previous unwanted pregnancies
Number of subjects: 2594
Study: 34864883

Group type: EXPERIMENTAL
Intervention: Aarau trauma prognostic longer-term outcome scoring (ATPLOS) system
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures (PROM)
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Univariate analysis of sociodemographic, injury-related, treatment, and early hospital outcome variables
Number of subjects: 1052
Study: 34864917

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 5619
Study: 34864930

Group type: EXPERIMENTAL
Intervention: Cluster A (purely axial)
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Cluster B (both axial and peripheral)
Number of subjects: 584
Study: 34864948

Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir (90mg/400mg) once daily for 12 weeks
Number of subjects: 111
Study: 34864959

Group type: EXPERIMENTAL
Intervention: Resilient FH (R-FH) defined by the presence of a pathogenic mutation causative of FH in patients aged ≥65 years without clinical ASCVD.
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Higher levels of HDL-C and lower 10-year score in SAFEHEART-RE.
Number of subjects: 930
Study: 34865019

Group type: EXPERIMENTAL
Intervention: Uterus transplantation (UTx) with embryo transfer (ET) attempted 12 months after transplantation.
Number of subjects: 7
Study: 34865064

Group type: EXPERIMENTAL
Intervention: Maternal SARS-CoV-2 infection
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Time between symptom onset and childbirth
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Older gestational age at birth
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Maternal IgG and placental transfer
Number of subjects: 87
Study: 34865085

Group type: COMPARATOR
Intervention: Amitriptyline, Topiramate, or Placebo (twice daily)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Serum drug levels
Number of subjects: 328

Group type: COMPARATOR
Intervention: Self-report and pill count adherence
Number of subjects: 328

Group type: COMPARATOR
Intervention: Serum drug levels at trial midpoint
Number of subjects: 328
Study: 34865186

Group type: EXPERIMENTAL
Intervention: Phenotype C
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Both phenotypes B and C
Number of subjects: 133
Study: 34865212

Group type: EXPERIMENTAL
Intervention: Single-agent ibrutinib (n=45)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Ibrutinib in combination with an anti-CD20 antibody (n=44)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both treatment groups (ibrutinib alone and in combination)
Number of subjects: 89
Study: 34866168

Group type: EXPERIMENTAL
Intervention: Darolutamide 600 mg orally twice daily
Number of subjects: 0
Study: 34866276

Group type: EXPERIMENTAL
Intervention: New-onset pain
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Clinically significant pain (NRS ≥3)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Neuropathic pain
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pain catastrophizing thoughts
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pain in ≥2 body sites
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Widespread pain
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Health-Related Quality of Life (HRQoL)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Mood disorders (HADS)
Number of subjects: 65
Study: 34866900

Group type: EXPERIMENTAL
Intervention: 550lx illuminance
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20lx illuminance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Illuminance requirement
Number of subjects: 0
Study: 34867148

Group type: EXPERIMENTAL
Intervention: Carriers of Val/Met (G/A) or Met (A/A) alleles
Number of subjects: 187

Group type: COMPARATOR
Intervention: Homozygous Val (G/G) carriers
Number of subjects: 187
Study: 34867275

Group type: EXPERIMENTAL
Intervention: Exercise intervention for 5 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher cardiorespiratory fitness
Number of subjects: 0
Study: 34867468

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34867586

Group type: EXPERIMENTAL
Intervention: Psychological support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study: 34867617

Group type: EXPERIMENTAL
Intervention: Family Communication Scale
Number of subjects: 0
Study: 34867626

Group type: EXPERIMENTAL
Intervention: Advanced Meditation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34867691

Group type: EXPERIMENTAL
Intervention: Thrive by Three intervention (10-month, multicomponent, in-service professional development)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 187
Study: 34867742

Group type: EXPERIMENTAL
Intervention: active vibrotactile coordinated reset (vCR) stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: inactive (sham) vibrotactile coordinated reset (vCR) stimulation
Number of subjects: 30
Study: 34868003

Group type: EXPERIMENTAL
Intervention: XAV-19
Number of subjects: 0
Study: 34868050

Group type: EXPERIMENTAL
Intervention: 81mg of ASA daily for 6 weeks
Number of subjects: 0
Study: 34868583

Group type: EXPERIMENTAL
Intervention: Cefiderocol
Number of subjects: 371

Group type: COMPARATOR
Intervention: Imipenem-cilastatin
Number of subjects: 371
Study: 34868614

Group type: EXPERIMENTAL
Intervention: ePRO app
Number of subjects: 44
Study: 34868671

Group type: EXPERIMENTAL
Intervention: FS-LASIK surgery
Number of subjects: 30
Study: 34868687

Group type: COMPARATOR
Intervention: Bilateral simple orchidectomy (BSO)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Bilateral subcapsular orchidectomy (BSCO)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Bilateral-epididymal-sparing orchidectomy (BESO)
Number of subjects: 63
Study: 34868736

Group type: EXPERIMENTAL
Intervention: Mindful yoga intervention
Number of subjects: 0
Study: 34868929

Group type: EXPERIMENTAL
Intervention: NIR-ICG imaging
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: NIR-ICG imaging combined with WL imaging
Number of subjects: 51
Study: 34869421

Group type: EXPERIMENTAL
Intervention: Time-varying intensity of ventilation
Number of subjects: 0
Study: 34869442

Group type: EXPERIMENTAL
Intervention: Positive Interferon-Gamma Release Assay
Number of subjects: 0
Study: 34869534

Group type: EXPERIMENTAL
Intervention: Early Time-Restricted Eating
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Late Time-Restricted Eating
Number of subjects: 0
Study: 34869651

Group type: EXPERIMENTAL
Intervention: Lipoprotein(a) levels
Number of subjects: 51500

Group type: EXPERIMENTAL
Intervention: Estimated Glomerular Filtration Rate (eGFR) levels
Number of subjects: 51500
Study: 34869938

Group type: EXPERIMENTAL
Intervention: Composite intervention including non-hormonal pharmacotherapy for VMS, digital cognitive behavioural therapy for insomnia, self-management strategies, and partner support
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Composite intervention
Number of subjects: 205
Study: 34869940

Group type: EXPERIMENTAL
Intervention: Medical education on SCI related topics offered by specialists to GPs practicing in rural areas.
Number of subjects: 395

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 395
Study: 34870025

Group type: EXPERIMENTAL
Intervention: Prenatal plus postnatal small-quantity lipid-based nutrient supplements (SQ-LNS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Prenatal iron and folic acid (IFA) supplementation
Number of subjects: 80
Study: 34870071

Group type: EXPERIMENTAL
Intervention: Short food-frequency questionnaire (SFFQ)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Comprehensive food-frequency questionnaire (CFFQ)
Number of subjects: 130
Study: 34870211

Group type: EXPERIMENTAL
Intervention: Deep learning convolutional neural network (CNN) enhancement of PET/MRI scans
Number of subjects: 20
Study: 34870215

Group type: EXPERIMENTAL
Intervention: Artificial Intelligence (AI) system applied to digital mammography (DM) examinations
Number of subjects: 14768

Group type: COMPARATOR
Intervention: Double reading performance
Number of subjects: 14768
Study: 34870321

Group type: COMPARATOR
Intervention: Carisbamate
Number of subjects: 2211
Study: 34870327

Group type: EXPERIMENTAL
Intervention: Immunotherapy (active immunotherapy Bacillus Calmette-Guérin (BCG), adoptive cell transfer, transfer factor (TF), tumour-infiltrating lymphocytes (TIL), dendritic cell/cytokine-induced killer (DC/CIK), antigen-specific cancer vaccines (MAGE-A3, L-BLP25), targeted natural killer (NK) cells)
Number of subjects: 5128

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 5128
Study: 34870630

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: V-SAFE technology
Number of subjects: 0
Study: 34870789

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 1777

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 1777
Study: 34870800

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 7844
Study: 34870878

Group type: EXPERIMENTAL
Intervention: Xentuzumab 750 mg/wk
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Xentuzumab 1000 mg/wk
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Xentuzumab 1000 mg/wk (expansion cohort)
Number of subjects: 21
Study: 34870940

Group type: EXPERIMENTAL
Intervention: Protective factors (self-efficacy for coping with cancer, spiritual well-being)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Revised resilience model
Number of subjects: 416
Study: 34871089

Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) at 25 mg once daily plus two investigator-selected NRTIs
Number of subjects: 0
Study: 34871104

Group type: EXPERIMENTAL
Intervention: hu14.18K322A with induction chemotherapy
Number of subjects: 64
Study: 34871175

Group type: EXPERIMENTAL
Intervention: BCI-controlled pedaling training system (BCI-PT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional pedaling training (Control)
Number of subjects: 30
Study: 34871178

Group type: EXPERIMENTAL
Intervention: Digital intervention using a virtual reality simulation and a mobile platform for monitoring stress indicators; duration of monitoring is 8 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational intervention at individual, team, and organizational levels; specific details on dosage and duration not provided.
Number of subjects: 0
Study: 34871190

Group type: EXPERIMENTAL
Intervention: Extracellular vesicles (EVs) from women with severe preeclampsia (sPE)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Extracellular vesicles (EVs) from normotensive pregnant women
Number of subjects: 29
Study: 34871241

Group type: EXPERIMENTAL
Intervention: s-Flt-1 at concentrations greater than 60 pg/ml
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: s-Flt-1 at concentrations greater than 70 pg/ml
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: PCT with at least 80% decrease or PCT less than 0.5 ng/ml on day 7
Number of subjects: 336
Study: 34871308

Group type: EXPERIMENTAL
Intervention: nAb titers measured in serum by SARS-CoV-2.D614G Spike-pseudotyped virus infection of 293T/ACE2 cells
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: nAb titers measured in serum
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: nAb ID50 (ID80) titers
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: nAb titers after SARS-CoV-2 infection
Number of subjects: 329
Study: 34871341

Group type: EXPERIMENTAL
Intervention: Strict containment and health policies
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: Less strict policies
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: Very strict policies
Number of subjects: 1256
Study: 34871370

Group type: EXPERIMENTAL
Intervention: 20S proteasome
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: IGF-1
Number of subjects: 9
Study: 34871371

Group type: EXPERIMENTAL
Intervention: Donor memory-like NK cells
Number of subjects: 9
Study: 34871427

Group type: EXPERIMENTAL
Intervention: Sorghum diet with lysine levels of 8.2, 12.5, and 15.7 mg.kg-1.d-1
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Complementation diet with lentils
Number of subjects: 5

Group type: COMPARATOR
Intervention: Reference diet with L-lysine levels of 5, 8, 12, and 15 mg.kg-1.d-1
Number of subjects: 5
Study: 34871570

Group type: EXPERIMENTAL
Intervention: Tafenoquine 100 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tafenoquine 150 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tafenoquine 200 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tafenoquine 300 mg
Number of subjects: 60
Study: 34871572

Group type: EXPERIMENTAL
Intervention: Clinical Decision Rule (DISCERN-FN) applied a posteriori
Number of subjects: 2345
Study: 34871698

Group type: EXPERIMENTAL
Intervention: Higher plasma lead concentration
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Plasma lead concentration at admission for transplant
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Plasma lead concentration after 3 months post-transplant
Number of subjects: 670
Study: 34871924

Group type: EXPERIMENTAL
Intervention: SCOPA-AUT questionnaire
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale (ESS)
Number of subjects: 70
Study: 34872106

Group type: EXPERIMENTAL
Intervention: TCRαβ/CD19-depleted HSCT
Number of subjects: 60